Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amfetamine/guanfacine - Genco Sciences

Next Previous
Drug Profile

Amfetamine/guanfacine - Genco Sciences

Latest Information Update: 28 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genco Sciences
  • Class Acetamides; Amphetamines; Centrally-acting antihypertensives; Chlorobenzenes; Guanidines; Phenylacetates; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Alpha 2 adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gilles de la Tourette's syndrome
  • New Molecular Entity No

Highest Development Phases

  • No development reported Gilles de la Tourette's syndrome

Most Recent Events

  • 28 May 2019 No recent reports of development identified for preclinical development in Gilles-de-la-Tourette's-syndrome(In adolescents, In children, In infants, In neonates) in USA
  • 07 Dec 2017 Chemical structure information added
  • 17 Mar 2016 Guanfacine/amphetamine - Genco Sciences receives Orphan Drug status for Gilles de la Tourette's syndrome in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top